Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > AGN phase 1 DMT study
View:
Post by StockDoctor101 on Jan 19, 2023 11:34am

AGN phase 1 DMT study

AGN is advancing phase 1 DMT clinical stroke study and the first subject has been dosed. Will be helpful in planning for phase 2 as well. AGN.c is the first company in the world to investigate DMT for stroke. Phase 1 will test 60 healthy patients and focus on the safety and tolerability of DMT. There are very few treatment options for the treatment of stroke so its great to see AGN move forward with this study. Data should be out in Q3 then phase 2 studies in stroke patients will begin at the end of year.

https://www.youtube.com/watch?v=BfjAjt1jxuU&t=1s
Be the first to comment on this post
Algernon Pharmaceuticals Inc.